8月28日，BioNTech盘前下跌11.62%，报99.36美元/股，成交额252.29万美元。
消息面上，辉瑞与BioNTech宣布其针对XFG变体的新冠疫苗获FDA批准，但适用范围仅限65岁及以上成年人以及5至64岁具有高风险基础疾病的人群，相较此前年份面向全人群接种的授权范围显著收窄，市场对其新冠疫苗收入前景进一步承压。此前公司Q2财报已大幅下调全年营收指引至16亿至19亿欧元，远低于分析师预期的21.6亿欧元，季度亏损亦超预期。受限的获批人群叠加持续恶化的基本面，令投资者信心进一步受挫。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.